No Data
Oppenheimer's Top SMID Ideas Within High-growth Themes
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $104
Oppenheimer analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $92 to $104.According to TipRanks data, the analyst has a su
Express News | MoonLake Immunotherapeutics : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $104
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On MoonLake With Outperform Rating, Announces Price Target of $104
Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake with a Outperform rating and announces Price Target of $104.